Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792013 | 1.00 | USP30 (0.37) | USP30RIPK1NSD2KCNA5ALOX5AP | |
| SCHEMBL12611574 | 0.86 | RIPK1 (0.37) | RIPK1KCNA5ALDH1A1 | |
| SCHEMBL1789975 | 0.80 | KCNA5 (0.45) | USP30KCNA5ALDH1A1 | |
| SCHEMBL1789973 | 0.80 | KCNA5 (0.45) | USP30KCNA5ALDH1A1 | |
| SCHEMBL1790761 | 0.74 | NSD2 (0.45) | NSD2ALOX5APFEN1ALDH1A1PARG | |
| SCHEMBL1790762 | 0.74 | NSD2 (0.45) | NSD2ALOX5APFEN1ALDH1A1PARG | |
| SCHEMBL1789779 | 0.73 | ALDH1A1 (0.55) | RIPK1KCNA5ALDH1A1 | |
| SCHEMBL1789777 | 0.73 | ALDH1A1 (0.55) | RIPK1KCNA5ALDH1A1 | |
| SCHEMBL14328457 | 0.71 | NSD2 (0.47) | NSD2ALOX5APFEN1ALDH1A1PARG | |
| SCHEMBL8105745 | 0.70 | NSD2 (0.41) | USP30NSD2ALOX5APFEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010002998-A1 | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | USP30 4498/4885RIPK1 4378/4885NSD2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.